✦ LIBER ✦

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

✍ Scribed by Jean-Michel Molina; Jaime Andrade-Villanueva; Juan Echevarria; Ploenchan Chetchotisakd; Jorge Corral; Neal David; Graeme Moyle; Marco Mancini; Lisa Percival; Rong Yang; Alexandra Thiry; Donnie McGrath

Book ID: 117303306
Publisher: The Lancet
Year: 2008
Tongue: English
Weight: 246 KB
Volume: 372
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(08)61081-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Final 192-week efficacy and safety of on

Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial

✍ Orkin, C; DeJesus, E; Khanlou, H; Stoehr, A; Supparatpinyo, K; Lathouwers, E; Le 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 303 KB